First in Human Study of SNV1521 With a RAS Inhibitor for People With Advanced Pancreatic Cancer

Starting soon · Phase 1

Conditions studied: Pancreatic Cancer, Pancreatic Acinar Carcinoma

In brief

This study is a Phase 1 clinical trial testing an oral investigational drug called SNV1521 together with a RAS-targeted cancer medicine in people with pancreatic cancer that cannot be removed by surgery or has spread. The main goals are to find doses of the drug combination that are safe and tolerable and to look for early signs that the treatment may help control the cancer. Participants will receive the study medicines in repeating cycles and will have regular blood tests, scans, and other exams to monitor side effects and how their cancer responds.

Key facts

Study ID
NCT07756281
Run by
Synnovation Therapeutics, Inc.
People needed
40
Starts
2026-09-01
Expected to finish
2029-06-01
Last updated by the study team
2026-08-10

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.